Compare APYX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APYX | AGEN |
|---|---|---|
| Founded | 1982 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.0M | 147.4M |
| IPO Year | 1995 | 1999 |
| Metric | APYX | AGEN |
|---|---|---|
| Price | $4.10 | $3.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $6.50 | ★ $14.50 |
| AVG Volume (30 Days) | 222.2K | ★ 889.8K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.40 | ★ 100.00 |
| EPS | N/A | ★ 1.02 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | $11.93 | $107.63 |
| Revenue Next Year | $11.01 | N/A |
| P/E Ratio | ★ N/A | $3.48 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $1.34 | $2.71 |
| 52 Week High | $4.50 | $7.34 |
| Indicator | APYX | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 58.22 | 45.15 |
| Support Level | $3.39 | $2.91 |
| Resistance Level | $4.28 | $4.25 |
| Average True Range (ATR) | 0.37 | 0.25 |
| MACD | 0.10 | -0.06 |
| Stochastic Oscillator | 81.52 | 35.51 |
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.